Cluster of Differentiation 19 (CD19)/B Cell Maturation Antigen (BCMA) Chimeric Antigen Receptor T-Cell (CAR-T) Therapy for Refractory Autoimmune Diseases
brief summary
This study is an investigator-initiated single center, single arm clinical study with a target population of patients with refractory autoimmune diseases. It is an early exploratory clinical study of the safety, tolerability and initial efficacy of CD19/BCMA CAR-T in the treatment of refractory autoimmune diseases.
detailed description
This open-label, single-arm clinical trial aims to evaluate the efficacy and safety of in vivo CAR-T cell therapy in patients with refractory autoimmune diseases.
No lymphodepletion conditioning regimen will be administered in this study. The lentiviral vector drug of CD19/BCMA-targeted CAR-T therapy will be infused directly.
Following infusion, subjects will undergo safety and efficacy assessments for up to 24 months to determine whether disease control is achieved.
official title
A Clinical Study on the Safety, Tolerability and Preliminary Efficacy of Targeted CD19/BCMA CAR-T Therapy in the Treatment of Refractory Autoimmune Diseases (ADs)